Carey Olsen, together with Northern Trust, have supported venture capital firm Pureos Bioventures on the successful launch and final close of its first fund, BB Pureos Bioventures LP (Pureos), with commitments of US$205 million.
Pureos, which exceeded its initial fundraising target after securing support from pharmaceutical and biotech companies, family offices, pension funds, fund-of-funds, a large contract manufacturer and other institutional investors, will invest globally but have a primary focus on Switzerland and Europe. It will invest in innovative private drug development companies with an emphasis on novel biological drugs and emerging modalities such as nucleic acid, cell and gene therapies.
Pureos Bioventures invests venture capital in private innovative drug development companies, with an emphasis on the next generation of biological drugs and drug formats.
The Carey Olsen team was led by partner Ben Morgan (Picture), assisted by senior associate James Cooke.
Involved fees earner: Ben Morgan – Carey Olsen; James Cooke – Ogier LLP; Law Firms: Carey Olsen; Ogier LLP; Clients: Pureos Bioventures ;